Fig. 5From: Olipudase alfa enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD): sustained improvements in clinical outcomes after 6.5 years of treatment in adultsGround Glass Appearance HRCT Images and Scores. Images and scores at baseline and through year 6 for the individual with the highest (worst) baseline scoreBack to article page